Description: Eutilex.Co.,Ltd. discovers and develops immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. It develops anti-tumor T cell therapy and antibody therapeutics. The company was founded in 2015 and is headquartered in Seoul, South Korea.
Home Page: www.eutilex.com
Daeryung Technotown 17
Seoul,
08594
South Korea
Phone:
82 2 3402 7315
Officers
| Name | Title |
|---|---|
| Dr. Byoung-Se Kwon Ph.D. | Founder & CEO |
| Mr. Edwin E. Kwon Esq. | Chief Financial Officer |
| Mr. Soo Young Choi Ph.D. | Chief Operating Officer |
| Mr. Mase Lee Ph.D. | Chief Technology Officer |
| Ms. So Heui Choe J.D., Ph.D. | Chief Compliance Officer |
| Mr. Jeonghoon Han Ph.D. | C.B.O. |
| Mr. Young Ho Kim Ph.D. | C.D.O |
| Yeong Cheol Kim Ph.D. | Chief Research Advisor |
Exchange: KQ
Country: KR
Currency: Korean Won (₩)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 76.5029 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 108 |